PLUS1
399.55
0.00 (0.00%)
0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | REGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.74 | 0.19% | 399.55 | 393.3913 | 402.09 | 399.10 | 398.81 | 23:59:40 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 388.00 | 425.00 | 37.00 | 8.71% | 4 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,302 | 536,829 | $ 400.25 | $ 214,865,689 | 861,855 | 271.37 - 445.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:47:41 | formt | 8,264 | $ 399.55 | USD |
Regeneron Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 43.96B | 110.02M | $ 2.44B | 18.45 | 21.60 | 108.28M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Regeneron Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/14/2020 | 17:48 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/14/2020 | 16:28 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/14/2020 | 16:21 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/14/2020 | 06:04 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 2/12/2020 | 16:01 | PR Newswire (US) | Regeneron Announces Upcoming Investor Conference.. |
| 2/12/2020 | 11:18 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 2/10/2020 | 16:46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REGN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 391.07 | 413.64 | 376.01 | 393.39 | 949,381 | 8.48 | 2.17% |
| 1 Month | 387.00 | 413.64 | 328.125 | 367.40 | 970,790 | 12.55 | 3.24% |
| 3 Months | 350.93 | 413.64 | 328.125 | 370.63 | 778,678 | 48.62 | 13.85% |
| 6 Months | 301.83 | 413.64 | 271.37 | 335.57 | 737,060 | 97.72 | 32.38% |
| 1 Year | 412.00 | 445.00 | 271.37 | 338.52 | 753,439 | -12.45 | -3.02% |
| 3 Years | 375.95 | 543.5518 | 271.37 | 373.13 | 795,917 | 23.60 | 6.28% |
| 5 Years | 402.00 | 605.9299 | 271.37 | 398.83 | 793,167 | -2.45 | -0.61% |
Regeneron Pharmaceuticals Description
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer. |
